Managing Self-funded Risk

Spotlight on kidney disease: Assessing and addressing the risks
April 02, 2024

Spotlight on kidney disease: Assessing and addressing the risks

Arthritis cost review: High-cost prescription and injectable drugs update
March 22, 2024

Arthritis cost review: High-cost prescription and injectable drugs update

2024 Updates and 2023 Year in Review on Leave and Accommodations Webinar
February 28, 2024

2024 Updates and 2023 Year in Review on Leave and Accommodations Webinar

Watch Marjory Robertson, AVP & Senior Counsel, Sun Life and Abigail O’Connell, Senior Counsel, Sun Life, for  a recap of 2023 legal and compliance developments related to leave and accommodation law. 

 2024 Future Forecast Video Series: Improving the Medical Moment
January 16, 2024

2024 Future Forecast Video Series: Improving the Medical Moment

2023 Updates on Leave and Accommodation laws
September 20, 2023

2023 Updates on Leave and Accommodation laws

Watch as Marjory Robertson, AVP & Senior Counsel, Sun Life U.S. and Abigail O’Connell, Senior Counsel, recap the latest 2023 leave and accommodation-related compliance developments. 

2023 High-cost claims and injectable drug trends analysis
May 17, 2023

2023 High-cost claims and injectable drug trends analysis

For the past eleven years, Sun Life has shared our data and insights with the self-funded marketplace to help employers and brokers understand trends around the highest-cost claims.

2023 Future Forecast with Jennifer Collier and James Slotnick
February 08, 2023

2023 Future Forecast with Jennifer Collier and James Slotnick

What's top of mind for Sun Life leaders?

Introduction to Gene Therapies (3rd edition)
February 06, 2023

Introduction to Gene Therapies (3rd edition)

Learn more about recently approved Hemgenix in the treatment of Hemophilia B, the gene therapy pipeline, the approval process, and what gene therapies are, in our second edition of the Introduction to Gene Therapies paper.

Impacts of Blood Cancer: Blood Cancer was the #2 high-cost claims condition and nearly 10% of 2021 total spend within Sun Life’s Health & Risk Solutions book of business
September 29, 2022

Impacts of Blood Cancer: Blood Cancer was the #2 high-cost claims condition and nearly 10% of 2021 total spend within Sun Life’s Health & Risk Solutions book of business

Every three minutes, someone in the U.S. is diagnosed with blood cancer. 

2022 Sun Life Stop-Loss Research Report: High-cost claims and injectable drug trends analysis
June 22, 2022

2022 Sun Life Stop-Loss Research Report: High-cost claims and injectable drug trends analysis

For the past ten years, Sun Life has shared our data and insights with the self-funded marketplace to help employers and brokers understand trends around the highest-cost claims.